Endocrine Abstracts

Type 1 diabetes mellitus (T1DM) not only is congenital disease that known as insulin-dependent diabetes, often occurs in children and adolescents. Recent advances in quantitative proteomics including fluorescence two-dimensional differential gel electrophoresis (2D-DIGE) and matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) have offered opportunities to discover plasma proteins as biomarkers for tracking the progression and for underst...

Obesity, characterized by excess intra-abdominal adipose tissue, is closely associated with a cluster of metabolic disorders such as type 2 diabetes mellitus (T2DM). Our previous study revealed significant associations between interleukin 4 (IL4) genotypes and T2DM, as well as IL4 genotypes and high density lipoprotein-cholesterol levels. Our most recent study results reveal that IL4 has anti-hyperglycemic function by improving insulin sensitivity and glucose tolerance. In add...

Objective: Metformin was considered as a weight lowering agent in diabetes patients, while it remained unclear in simple obesity patients. We aimed to investigate if metformin is effective and safe in the therapy of normoglycemic obesity.Methods: We systematically searched MEDLINE (1950–2011), EMBase (1950–2011), and CCTR (4th Issue 2011), and collected and screened all randomized controlled trials compared metformin and placebo in obese partic...

Introduction: Using the criterion of GH<2.5 μg/l and normalized IGF1, response rates to currently available somatostatin analogues in medically-naïve patients with acromegaly are 20–25% after 12 m. The broader somatostatin receptor binding profile of pasireotide may potentially improve response rates. This randomized, double-blind 12-m study compared pasireotide LAR with octreotide LAR.Methods: Patients with acromegaly (GH>5 μ...

Introduction: In a large, randomized, double-blind, phase III trial in patients with acromegaly, pasireotide LAR was significantly more effective than octreotide LAR at inducing GH<2.5 μg/l and normal IGF1 after 12 months of therapy (core study). The crossover phase of this trial allowed patients without full biochemical control at month 12 to switch treatments. This abstract reports the results of patients who switched therapy.Methods: Medicall...